Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.00 EUR
Change Today -0.96 / -1.55%
Volume 4.2K
ZEG On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 11:38 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

of diabetic nephropathy. In September 2014, AstraZeneca plc and Eli Lilly and Co. announced that they reached a deal to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme or BACE inhibitor currently in development as a potential treatment for Alzheimer's disease. In October 2014, AstraZeneca and Pharmacyclics Inc. announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. In November 2014, Isis Pharmaceuticals, Inc. and AstraZeneca announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. In November 2014, AstraZeneca, Pharmacyclics Inc. and Janssen Research & Development LLC have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech Inc. In February 2015, University of Texas MD Anderson Cancer Center and AstraZeneca have entered into a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers. In February 2015, AstraZeneca has entered into a research collaboration with compatriot Orca Pharmaceuticals, develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR) for treating autoimmune diseases. In March 2015, AstraZeneca and Cambridge Judge Business School announced collaboration to identify and support biotech start-ups AstraZeneca and the Cambridge Judge Business School at the University of Cambridge announced an agreement to deliver a new Accelerate Cambridge Life Sciences programme at the business school which would identify, train and mentor start-up ventures in the life sciences. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €61.00 EUR -0.96

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.64 USD -1.22
Biogen Idec Inc $417.63 USD -7.98
Celgene Corp $118.03 USD -2.68
Eli Lilly & Co $68.41 USD -2.18
Novo Nordisk A/S kr321.10 DKK +3.10
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 70.1x
Price/Sales 3.3x
Price/Book 4.4x
Price/Cash Flow 70.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.